DK0876387T3 - Anvendelse af roxithromycin til fremstilling af et lægemiddel til forögelse af den biologiske og antivirale aktivitet af proteaseinhibitorer - Google Patents

Anvendelse af roxithromycin til fremstilling af et lægemiddel til forögelse af den biologiske og antivirale aktivitet af proteaseinhibitorer

Info

Publication number: DK0876387T3
Authority: DK; Denmark
Prior art keywords: protease inhibitors; roxithromycin; drug; biological; preparation
Prior art date: 1995-08-30

Application number

DK96929058T

Other languages

English (en)

Inventor

Raymond F Schinazi

Jean-Pierre Sommadossi

Original Assignee

Uab Research Foundation

Raymond F Schinazi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-30

Filing date

1996-08-30

Publication date

2006-05-29

1996-08-30 Application filed by Uab Research Foundation, Raymond F Schinazi filed Critical Uab Research Foundation

2006-05-29 Application granted granted Critical

2006-05-29 Publication of DK0876387T3 publication Critical patent/DK0876387T3/da

Links

239000000137 peptide hydrolase inhibitor Substances 0.000 title abstract 4
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title abstract 2
239000003814 drug Substances 0.000 title abstract 2
RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 title 1
230000000840 anti-viral effect Effects 0.000 title 1
230000004071 biological effect Effects 0.000 title 1
229940079593 drug Drugs 0.000 title 1
229960005224 roxithromycin Drugs 0.000 title 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 abstract 2
229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
239000003242 anti bacterial agent Substances 0.000 abstract 1
229940088710 antibiotic agent Drugs 0.000 abstract 1
230000004700 cellular uptake Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000004030 hiv protease inhibitor Substances 0.000 abstract 1
239000003120 macrolide antibiotic agent Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
- C07H15/16—Lincomycin; Derivatives thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biochemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
AIDS & HIV (AREA)
Crystallography & Structural Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK96929058T 1995-08-30 1996-08-30 Anvendelse af roxithromycin til fremstilling af et lægemiddel til forögelse af den biologiske og antivirale aktivitet af proteaseinhibitorer DK0876387T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US08/521,474 US5750493A (en)	1995-08-30	1995-08-30	Method to improve the biological and antiviral activity of protease inhibitors

Publications (1)

Publication Number	Publication Date
DK0876387T3 true DK0876387T3 (da)	2006-05-29

Family

ID=24076871

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96929058T DK0876387T3 (da)	1995-08-30	1996-08-30	Anvendelse af roxithromycin til fremstilling af et lægemiddel til forögelse af den biologiske og antivirale aktivitet af proteaseinhibitorer

Country Status (11)

Country	Link
US (1)	US5750493A (da)
EP (1)	EP0876387B1 (da)
JP (1)	JP4335311B2 (da)
KR (1)	KR100454663B1 (da)
AT (1)	ATE314116T1 (da)
AU (1)	AU716821B2 (da)
DE (1)	DE69635671T2 (da)
DK (1)	DK0876387T3 (da)
ES (1)	ES2257752T3 (da)
PT (1)	PT876387E (da)
WO (1)	WO1997008180A1 (da)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849911A (en) *	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
EP0955054A4 (en) *	1996-11-08	2003-01-29	Japan Energy Corp	AIDS CURE
US6180634B1 (en) *	1997-11-13	2001-01-30	Merck & Co., Inc.	Combination therapy for the treatment of AIDS
ES2140329B1 (es) *	1997-12-04	2000-10-16	Univ Granada	Utilizacion de acido maslinico como inhibidor de proteasas para el tratamiento de la enfermedad causada por los virus de la inmunodeficiencia adquirida.
US6436989B1 (en) *	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US6734192B1 (en)	1999-08-23	2004-05-11	Mp-1 Inc.	Treatment of viral infections
ITMI992711A1 (it) *	1999-12-27	2001-06-27	Novartis Ag	Composti organici
ATE432691T1 (de) *	2000-03-28	2009-06-15	Sandoz Ag	Geschmackmaskierte granulierte teilchen
US6566401B2 (en) *	2001-03-30	2003-05-20	The Board Of Trustees Of The Leland Stanford Junior University	N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
EP1265073A3 (en) *	2001-06-05	2003-11-26	Tibotec Pharmaceuticals Ltd.	Methods for determining plasma free drug concentration
EP1483277A4 (en)	2002-02-15	2007-10-03	Merckle Gmbh	CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND USE, FORMULATION AND PHARMACEUTICAL APPLICATIONS THEREOF
US20040186063A1 (en) *	2002-02-15	2004-09-23	Hans-Jurgen Gutke	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2003211113B2 (en) *	2002-02-15	2007-08-09	Merckle Gmbh	Antibiotic conjugates
US20040005641A1 (en) *	2002-02-15	2004-01-08	Michael Burnet	Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
CA2474671A1 (en) *	2002-02-22	2003-08-28	Tibotec Bvba	Methods for determining the influence of protein binding on antiretroviral activity
US20040197321A1 (en) *	2002-03-19	2004-10-07	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20030180279A1 (en) *	2002-03-19	2003-09-25	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20050239054A1 (en) *	2002-04-26	2005-10-27	Arimilli Murty N	Method and compositions for identifying anti-HIV therapeutic compounds
TW200408645A (en) *	2002-04-26	2004-06-01	Gilead Sciences Inc	Non nucleoside reverse transcriptase inhibitors
PL376474A1 (en) *	2002-10-31	2005-12-27	Metabasis Therapeutics, Inc.	Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs
US7553844B2 (en)	2003-02-21	2009-06-30	Jarrow Formulas, Inc.	Methods for treatment of HIV or malaria using combinations of chloroquine and protease inhibitors
WO2005002626A2 (en) *	2003-04-25	2005-01-13	Gilead Sciences, Inc.	Therapeutic phosphonate compounds
SG182849A1 (en) *	2003-04-25	2012-08-30	Gilead Sciences Inc	Antiviral phosphonate analogs
US7427636B2 (en) *	2003-04-25	2008-09-23	Gilead Sciences, Inc.	Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2004096285A2 (en) *	2003-04-25	2004-11-11	Gilead Sciences, Inc.	Anti-infective phosphonate conjugates
EP1620109A2 (en) *	2003-04-25	2006-02-01	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
US20090247488A1 (en) *	2003-04-25	2009-10-01	Carina Cannizzaro	Anti-inflammatory phosphonate compounds
US7470724B2 (en) *	2003-04-25	2008-12-30	Gilead Sciences, Inc.	Phosphonate compounds having immuno-modulatory activity
US20050261237A1 (en) *	2003-04-25	2005-11-24	Boojamra Constantine G	Nucleoside phosphonate analogs
CN101410120A (zh) *	2003-04-25	2009-04-15	吉里德科学公司	抗炎的膦酸酯化合物
US7407965B2 (en) *	2003-04-25	2008-08-05	Gilead Sciences, Inc.	Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) *	2003-04-25	2008-11-18	Gilead Sciences, Inc.	Anti-cancer phosphonate analogs
US7432261B2 (en) *	2003-04-25	2008-10-07	Gilead Sciences, Inc.	Anti-inflammatory phosphonate compounds
WO2005044279A1 (en) *	2003-10-24	2005-05-19	Gilead Sciences, Inc.	Purine nucleoside phosphonate conjugates
WO2005042773A1 (en) *	2003-10-24	2005-05-12	Gilead Sciences, Inc.	Methods and compositions for identifying therapeutic compounds
US7432273B2 (en) *	2003-10-24	2008-10-07	Gilead Sciences, Inc.	Phosphonate analogs of antimetabolites
BRPI0418031A (pt) *	2003-12-22	2007-04-17	Gilead Sciences Inc	inibidores de quinase fosfonato-substituìdos
BRPI0417988A (pt) *	2003-12-22	2007-04-27	Gilead Sciences Inc	análogos de fosfonato antivirais
US20050153990A1 (en) *	2003-12-22	2005-07-14	Watkins William J.	Phosphonate substituted kinase inhibitors
PT2258376T (pt)	2004-07-27	2019-05-31	Gilead Sciences Inc	Análogos fosfonatados de compostos inibidores do vih
RU2008106915A (ru) *	2005-07-26	2009-09-10	Меркле Гмбх (De)	Макролидные конъюгаты пирролиновых и индолизиновых соединений
MX2008007790A (es) *	2005-12-22	2009-03-04	Anaborex Inc	Composiciones y metodos para la prevencion y tratamiento de caquexia.
KR20100033378A (ko) *	2007-06-22	2010-03-29	브리스톨-마이어스 스큅 컴퍼니	아타자나비르를 함유하는 정제 조성물
PL2170292T3 (pl) *	2007-06-22	2014-06-30	Bristol Myers Squibb Holdings Ireland	Tabletkowane kompozycje zawierające atazanawir
DE602008005462D1 (de) *	2007-06-22	2011-04-21	Bristol Myers Squibb Co	Tablettierte atazanavirhaltige zusammensetzungen
CN101795674A (zh) *	2007-06-22	2010-08-04	百时美施贵宝公司	含有阿扎那韦的压片组合物
BRPI0915878A2 (pt)	2008-07-08	2015-11-03	Gilead Sciences Inc	sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
US20100021505A1 (en) *	2008-07-28	2010-01-28	Tibor Sipos	Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
EP3623364A1 (en)	2014-02-13	2020-03-18	Ligand Pharmaceuticals, Inc.	Prodrug compounds and their uses
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
FR3049861A1 (fr) *	2016-04-07	2017-10-13	Univ Claude Bernard Lyon	Nouvelles compositions antivirales pour le traitement de la grippe
PT3661937T (pt)	2017-08-01	2021-09-24	Gilead Sciences Inc	Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
WO2019139919A1 (en)	2018-01-09	2019-07-18	Ligand Pharmaceuticals, Inc.	Acetal compounds and therapeutic uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE913840A1 (en) *	1990-11-20	1992-05-20	Abbott Lab	Retroviral protease inhibiting compounds
US5461067A (en) *	1993-02-25	1995-10-24	Abbott Laboratories	Retroviral protease inhibiting compounds
US6037157A (en) *	1995-06-29	2000-03-14	Abbott Laboratories	Method for improving pharmacokinetics

1995
- 1995-08-30 US US08/521,474 patent/US5750493A/en not_active Expired - Lifetime
1996
- 1996-08-30 JP JP51050297A patent/JP4335311B2/ja not_active Expired - Fee Related
- 1996-08-30 AT AT96929058T patent/ATE314116T1/de not_active IP Right Cessation
- 1996-08-30 AU AU68601/96A patent/AU716821B2/en not_active Ceased
- 1996-08-30 ES ES96929058T patent/ES2257752T3/es not_active Expired - Lifetime
- 1996-08-30 PT PT96929058T patent/PT876387E/pt unknown
- 1996-08-30 DK DK96929058T patent/DK0876387T3/da active
- 1996-08-30 EP EP96929058A patent/EP0876387B1/en not_active Expired - Lifetime
- 1996-08-30 KR KR10-1998-0701498A patent/KR100454663B1/ko not_active Expired - Fee Related
- 1996-08-30 DE DE69635671T patent/DE69635671T2/de not_active Expired - Lifetime
- 1996-08-30 WO PCT/US1996/013721 patent/WO1997008180A1/en not_active Ceased

Also Published As

Publication number	Publication date
JP4335311B2 (ja)	2009-09-30
ATE314116T1 (de)	2006-01-15
JP2001500471A (ja)	2001-01-16
EP0876387B1 (en)	2005-12-28
EP0876387A4 (en)	1999-12-01
DE69635671T2 (de)	2006-09-07
EP0876387A1 (en)	1998-11-11
ES2257752T3 (es)	2006-08-01
DE69635671D1 (de)	2006-02-02
KR19990044262A (ko)	1999-06-25
KR100454663B1 (ko)	2004-12-29
PT876387E (pt)	2006-05-31
AU716821B2 (en)	2000-03-09
US5750493A (en)	1998-05-12
AU6860196A (en)	1997-03-19
WO1997008180A1 (en)	1997-03-06

Publication	Publication Date	Title
PT876387E (pt)	2006-05-31	Utilizacao de roxitromicina para a preparacao de um medicamento para melhorar a actividade biologica e antiviral de inibidores da protease
ATE276764T1 (de)	2004-10-15	Camptothecin arzneimittelkombinationen mit verringerten nebenwirkungen
BG100455A (en)	1997-09-30	Hiv protease inhibitors
TR199903331T2 (xx)	2000-06-21	Farnesil protein transferas engelleyicileri.
EP0679092A4 (en)	1997-11-19	CYTOKINE RESTRICTION AGENTS.
ES2133807T3 (es)	1999-09-16	Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
WO2004035747A3 (en)	2005-11-17	Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
WO2003034803A3 (en)	2003-10-02	Methods for determining toxicity reversing agents
EP1289559B8 (de)	2005-09-28	Kombinationen von enzyminhibitoren umfassende zubereitungen und deren verwendung
DK0836485T3 (da)	2002-09-30	Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
DK0839026T3 (da)	2002-01-21	Micellære polyether-blokcopolymerkompositioner til målretning af biologiske midler
TR200100054T2 (tr)	2001-06-21	Paroksetin metansülfonat
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
PT1272199E (pt)	2005-05-31	Terapias de combinacao com actividade de lesao vascular
DE59813162D1 (de)	2005-12-08	Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
ATE139226T1 (de)	1996-06-15	Aminosulfonylharnstoff-acat-inhibitoren
BR0206819A (pt)	2004-02-03	Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
DE59809283D1 (de)	2003-09-18	Inhibitoren für den urokinaserezeptor
MXPA04001912A (es)	2004-07-23	Aminobenzofenonas novedosas.
ATE291586T1 (de)	2005-04-15	Humanes antibiotisches protein
IL106237A0 (en)	1993-11-15	Piperidyl amides,sulfonamides and sulfoxamides as inhibitors of cholesterol biosynthesis
NO990322L (no)	1999-03-24	Farmas°ytisk blanding inneholdende en 5HT2c-antagonist og en D2-antagonist
IT1290910B1 (it)	1998-12-14	2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive
ATE364180T1 (de)	2007-06-15	Screeningverfahren mit bnpi und dnpi
DK1458391T3 (da)	2008-01-07	Fremgangsmåde til at behandle bakterielle infektioner ved anvendelse af gemifloxacin eller et salt deraf og et beta-lactamantibiotikum